Baker S, Mou B, Jiang W, Liu M, et al. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial. Int J Radiat Oncol Biol Phys 2022;114:849-855.
PMID: 36302495